XML 159 R65.htm IDEA: XBRL DOCUMENT
v3.20.4

Collaboration Agreements - MERCK Composition of the Total Transaction Price (Details) - USD ($) $ in Thousands | 12 Months Ended |
--- | --- | ---
Dec. 31, 2020 | Dec. 31, 2019 | Jan. 01, 2019
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |
Remaining performance obligations | $ 87,225 |  |
Decrease to the transaction price | 7,100 |  |
Merck agreement 2015 |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |
Remaining performance obligations | 52,647 | $ 59,735 | $ 65,000
Decrease to the transaction price | (12,353) | (5,265) |
Merck agreement 2015 | Upfront payment |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |
Remaining performance obligations | 60,000 | 60,000 | $ 60,000
Merck agreement 2015 | Upfront Payment, Research And Development |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |
Remaining performance obligations | $ 5,000 | $ 5,000 |

X
- Definition Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_MerckAgreement2015Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |